Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

Alterity Therapeutics AAN Presentation 5 May 2019

May 6, 2019May 27, 2019 Alterity Therapeutics

Alterity Therapeutics AAN Presentation 5 May 2019 Download

Post navigation

Initial data for Alterity Therapeutics Phase 1 clinical trial released at American Academy of Neurology Annual Meeting

Alterity Therapeutics commences US investor meetings following positive clinical data

Related Posts

Prana Biotechnology announces top line results of Phase 2 IMAGINE trial of PBT2 in Alzheimer’s disease

March 31, 2014

Prana Enrolls First Patient in the “Reach2HD” Phase II Huntington Disease Trial

July 17, 2013

XBRL 30 June 2020 filed with the SEC

September 16, 2020September 16, 2020

Leave a Reply Cancel reply

Your email address will not be published.Required fields are marked *

Save my name, email, and website in this browser for the next time I comment.

Δ

Recent Posts

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program
Presentation of New Biomarker Data at Scientific Congress
XBRL 30 June 2021 filed with the SEC
Alterity Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer’s and Parkinson’s
Quarterly Cash Flow Report

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065